TY - JOUR
T1 - Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
AU - Schön, Martin
AU - Zaharia, Oana P.
AU - Strassburger, Klaus
AU - Kupriyanova, Yuliya
AU - Báodis, Káalmáan
AU - Heilmann, Geronimo
AU - Strom, Alexander
AU - Böonhof, Gidon J.
AU - Michelotti, Filippo
AU - Yurchenko, Iryna
AU - Möoser, Clara
AU - Huttasch, Maximilian
AU - Bombrich, Maria
AU - Kelm, Malte
AU - Burkart, Volker
AU - Schrauwen-Hinderling, Vera B.
AU - Wagner, Robert
AU - Roden, Michael
AU - for the GDS Group
N1 - Publisher Copyright:
© 2023 by the American Diabetes Association.
PY - 2023/10
Y1 - 2023/10
N2 - Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent1 H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO2max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ~30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ~36% and ~62% lower compared with type 1 diabetes and control subjects, re-spectively. After 5 years, the M-value decreased by ~29% in type 1 and ~13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO2max. IMCL also associated with micro-albuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications.
AB - Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent1 H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO2max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ~30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ~36% and ~62% lower compared with type 1 diabetes and control subjects, re-spectively. After 5 years, the M-value decreased by ~29% in type 1 and ~13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO2max. IMCL also associated with micro-albuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications.
UR - https://www.scopus.com/pages/publications/85171900074
U2 - 10.2337/db23-0353
DO - 10.2337/db23-0353
M3 - Article
C2 - 37478166
AN - SCOPUS:85171900074
SN - 0012-1797
VL - 72
SP - 1483
EP - 1492
JO - Diabetes
JF - Diabetes
IS - 10
ER -